Blue Venture Fund is set to exit the medical diagnostics software provider in a flotation with a $75m placeholder target.

Third Rock Ventures has led a series A round for Abata Therapeutics that also featured fellow existing investor ElevateBio.

Third Rock Ventures has led a series A round for Abata Therapeutics, launched by the firm to commercialise research from Harvard, MIT, Johns Hopkins, NIH and UZH.

The eyewear retailer’s Lenskart Vision Fund will invest in eyecare and retail technology developers on behalf of its corporate parent.

Gilead Sciences, Yipinhong Pharmaceutical and Mass General Brigham Ventures helped the slow-release drug developer secure series C cash bringing its overall funding to almost $250m.

GV participated in a series C round for the fertility and gynaecology services provider at a $612m valuation, doubling its overall funding.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Waste management software provider Recycle Track Systems bagged $35m in a Citi-led series C round while muscular dystrophy drug developer Vita Therapeutics completed a $32m series A.

The AstraZeneca, Sinopharm and Eli Lilly-backed oncology drug developer has revealed its intention to go public in a Hong Kong IPO that could reportedly fetch $250m.

Gene therapy developer Corlieve, which utilises University of Bordeaux, Aix Marseille University, CNRS and Inserm research, is set to be acquired by peer QniQure for about $55m.